Analyst Reco. Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.185 ^USD	-4.44%		+3.95%	+17.33%

May. 15	Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating	MT
May. 14	Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating	May. 15	MT
Wedbush Lowers Passage Bio's Price Target to $3 From $5, Maintains Outperform Rating	Nov. 13	MT
Chardan Trims Price Target on Passage Bio to $9 From $11, Keeps Buy Rating	23-08-08	MT
Raymond James Trims Price Target on Passage Bio to $9 From $10, Keeps Outperform Rating	23-05-12	MT
Chardan Cuts Price Target on Passage Bio to $11 From $18, Keeps Buy Rating	22-12-15	MT
Citigroup Adjusts Price Target on Passage Bio to $5 From $7, Maintains Buy Rating	22-11-11	MT
Guggenheim Adjusts Price Target on Passage Bio to $11 From $13, Maintains Buy Rating	22-11-11	MT
Wedbush Trims Passage Bio's Price Target to $5 From $6, Keeps Outperform Rating	22-11-11	MT
Canaccord Genuity Starts Passage Bio at Buy With $8 Price Target	22-11-08	MT
Chardan Research Lowers Passage Bio's Price Target to $18 From $34, Maintains Buy Rating	22-08-05	MT
Wedbush Adjusts Passage Bio Price Target to $6 From $9, Maintains Outperform Rating	22-08-04	MT
Goldman Sachs Adjusts Price Target for Passage Bio to $2 From $4, Maintains Neutral Rating	22-05-17	MT
Raymond James Adjusts Passage Bio's Price Target to $10 from $24, Keeps Outperform Rating	22-05-17	MT
Wedbush Cuts Passage Bio's Price Target to $9 From $16, Citing PBKR03 Update, PBFT02 Timeline; Outperform Rating Kept	22-05-17	MT
Citigroup Adjusts Price Target on Passage Bio to $10 From $15, Reiterates Buy Rating	22-05-17	MT
Chardan Research Adjusts Passage Bio's Price Target to $34 From $43; Buy Rating Kept	22-03-11	MT
JPMorgan Downgrades Passage Bio to Neutral From Overweight	22-03-08	MT
Raymond James Adjusts Passage Bio's Price Target to $24 From $29, Keeps Outperform Rating	22-03-04	MT
Goldman Sachs Analyst Starts Passage Bio at Neutral, Down From Buy, Sets $6 Price Target	22-01-19	MT
BTIG Adjusts Passage Bio's Price Target to $16 From $25, Reiterates Buy Rating	22-01-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Passage Bio, Inc.

Equities

PASG

US7027121000

Analyst Reco.

Filters